Goldman Sachs’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $131M | Buy |
1,478,059
+1,208,121
| +448% | +$88.2M | 0.01% | 1025 |
|
|
2026
Q1 | $13.6M | Sell |
269,938
-5,127
| -2% | -$193K | ﹤0.01% | 2794 |
|
|
2025
Q4 | $9.01M | Sell |
275,065
-54,468
| -17% | -$1.42M | ﹤0.01% | 3194 |
|
|
2025
Q3 | $5.52M | Sell |
329,533
-193,883
| -37% | -$3.16M | ﹤0.01% | 3549 |
|
|
2025
Q2 | $7.84M | Buy |
523,416
+326,348
| +166% | +$4.83M | ﹤0.01% | 2986 |
|
|
2025
Q1 | $3.18M | Sell |
197,068
-550,484
| -74% | -$11.5M | ﹤0.01% | 3787 |
|
|
2024
Q4 | $17.4M | Buy |
747,552
+578,238
| +342% | +$17M | ﹤0.01% | 2268 |
|
|
2024
Q3 | $4.98M | Sell |
169,314
-723,769
| -81% | -$20.2M | ﹤0.01% | 3349 |
|
|
2024
Q2 | $21M | Buy |
893,083
+653,168
| +272% | +$22M | ﹤0.01% | 1853 |
|
|
2024
Q1 | $9.1M | Buy |
+239,915
| New | +$6.95M | ﹤0.01% | 2547 |
|
|
2023
Q3 | – | Sell |
-22,346
| Closed | -$252K | – | 5846 |
|
|
2023
Q2 | $252K | Buy |
+22,346
| New | +$106K | ﹤0.01% | 5098 |
|
|
2022
Q4 | – | Sell |
-36,628
| Closed | -$482K | – | 6259 |
|
|
2022
Q3 | $482K | Sell |
36,628
-10,864
| -23% | -$134K | ﹤0.01% | 5007 |
|
|
2022
Q2 | $600K | Buy |
47,492
+2,500
| +6% | +$87.6K | ﹤0.01% | 4953 |
|
|
2022
Q1 | $2.59M | Sell |
44,992
-382
| -0.8% | -$32.1K | ﹤0.01% | 3999 |
|
|
2021
Q4 | $5.39M | Sell |
45,374
-68
| -0.1% | -$10.7K | ﹤0.01% | 3335 |
|
|
2021
Q3 | $9.03M | Buy |
45,442
+200
| +0.4% | +$35K | ﹤0.01% | 2829 |
|
|
2021
Q2 | $7.87M | Sell |
45,242
-225
| -0.5% | -$40.9K | ﹤0.01% | 2921 |
|
|
2021
Q1 | $9M | Buy |
45,467
+28,078
| +161% | +$5.39M | ﹤0.01% | 2660 |
|
|
2020
Q4 | $3.42M | Sell |
17,389
-520
| -3% | -$108K | ﹤0.01% | 3304 |
|
|
2020
Q3 | $3.17M | Sell |
17,909
-280
| -2% | -$51.8K | ﹤0.01% | 3249 |
|
|
2020
Q2 | $4.21M | Buy |
18,189
+1,326
| +8% | +$253K | ﹤0.01% | 2928 |
|
|
2020
Q1 | $1.97M | Sell |
16,863
-819
| -5% | -$139K | ﹤0.01% | 3315 |
|
|
2019
Q4 | $3.38M | Buy |
17,682
+282
| +2% | +$55.4K | ﹤0.01% | 3252 |
|
|
2019
Q3 | $3.35M | Buy |
17,400
+1,557
| +10% | +$303K | ﹤0.01% | 3151 |
|
|
2019
Q2 | $2.71M | Sell |
15,843
-294
| -2% | -$50.8K | ﹤0.01% | 3319 |
|
|
2019
Q1 | $3.25M | Buy |
16,137
+15,430
| +2,182% | +$3.22M | ﹤0.01% | 3293 |
|
|
2018
Q4 | $132K | Sell |
707
-59
| -8% | -$12.5K | ﹤0.01% | 4946 |
|
|
2018
Q3 | $183K | Buy |
766
+80
| +12% | +$18.7K | ﹤0.01% | 4944 |
|
|
2018
Q2 | $181K | Buy |
686
+210
| +44% | +$51.7K | ﹤0.01% | 5015 |
|
|
2018
Q1 | $118K | Buy |
+476
| New | +$86K | ﹤0.01% | 5223 |
|
|
2017
Q1 | – | Sell |
-415
| Closed | -$45K | – | 6997 |
|
|
2016
Q4 | $45K | Sell |
415
-906
| -69% | -$132K | ﹤0.01% | 6415 |
|
|
2016
Q3 | $212K | Sell |
1,321
-928
| -41% | -$129K | ﹤0.01% | 5779 |
|
|
2016
Q2 | $273K | Buy |
+2,249
| New | +$431K | ﹤0.01% | 5429 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Goldman Sachs's SYRE Position: Q2 2026 in Review
Goldman Sachs increased its Spyre Therapeutics (SYRE) stake by 448% in Q2 2026, buying an estimated $88.2M and bringing the position to 1,478,059 shares worth $131M. The position accounts for 0.01% of the portfolio, ranked #1025.
Goldman Sachs first reported a position in SYRE in Q2 2016 and has held it in 33 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Goldman Sachs held 1,478,059 shares of Spyre Therapeutics worth $131M as of Q2 2026.
- Goldman Sachs bought 1,208,121 Spyre Therapeutics shares in Q2 2026, an estimated $88.2M.
- Spyre Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1025 holding.
- Goldman Sachs first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 33 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.